Web Results

Boehringer Ingelheim Pharmaceuticals, Inc. | Federal Trade ...

www.ftc.gov/enforcement/cases-proceedings/091-0023/boehringer-ingelheim-pharmaceuticals-inc

Feb 20, 2015 ... application/pdf icon FTC v. Boehringer Ingelheim Pharmaceuticals, Inc. (D.C. Cir. ), Response of FTC to Petition for Rehearing En Banc (113.12 ...

TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

www.leagle.com/decision/1995235234Conn1_1235/TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

Lawyer, Attorney, Counsel, Law Firm, & then ANUSHAVAN G. TOROSYAN v. ... action alleging that the defendant, Boehringer Ingelheim Pharmaceuticals, Inc...

In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation

www.law360.com/cases/502983dbe1a1455469000001

Boehringer Ingelheim International GmbH has agreed to pay roughly $650 million to settle claims in multidistrict ... Richard W Cohen, Lowey Dannenberg et al.

Validation of the multivariable In-hospital Mortality for PulmonAry ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4636647/

Oct 28, 2015 ... Coleman et al derived such a multivariable benchmarking rule for in-hospital .... performed using SAS V.9.2 (SAS Institute Inc, Cary, North Carolina, USA) or .... Berlin, Germany; and Boehringer-Ingelheim Pharmaceuticals, Inc, ...

LIU v. COOK COUNTY | FindLaw

caselaw.findlaw.com/us-7th-circuit/1729119.html

Mar 15, 2016 ... COOK COUNTY, et al., Defendants–Appellees. ... Coleman v. ..... Boehringer Ingelheim Pharmaceuticals, Inc., 627 F.3d 596, 601 (7th Cir.2010) ...

PDF(111K) - Wiley Online Library

onlinelibrary.wiley.com/doi/10.1002/clc.22565/pdf

rivaroxaban vs prior VKA) for ACTS burden and benefit scores were calculated ... Boehringer Ingelheim Pharmaceuticals Inc., Daiichi Sankyo Company, and Portola Pharmaceuticals. .... C. Coleman et al: Rivaroxaban and patient satisfaction.

2015 Middle District of Florida U.S. Federal District Court Case Law ...

law.justia.com/cases/federal/district-courts/florida/flmdce/2015/

Performance Plumbing of Southwest Florida, Inc. et al. Date: December 29, 2015 .... Absolute Activist Value Master Fund Limited et al v. Devine Date: December ... Peters v. Boehringer-Ingelheim Pharmaceuticals, Inc. ... Coleman v. Starbucks

American Bar Association - Ballotpedia

ballotpedia.org/American_Bar_Association

Oct 17, 2016 ... A. Schwarzenegger et al. v. M. Plata and R. Coleman, et al. J.D.B. v. State of ... at Austin, et al. Boehringer Ingelheim Pharmaceuticals, Inc. v.

Doses of apixaban and rivaroxaban prescribed in real-world United ...

www.tandfonline.com/doi/full/10.1185/03007995.2016.1170672

Apr 1, 2016 ... Keywords: Apixaban, Atrial fibrillation, Drug prescriptions, .... relative (0.6% absolute) higher use of reduced dose rivaroxaban vs. .... Boehringer-Ingelheim Pharmaceuticals Inc., Bayer Pharma A.G., ... Craig I. Coleman et al.

Comparative Efficacy and Safety of Antidiabetic Drug Regimens ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0125879

Apr 28, 2015 ... All agents significantly reduced HbA1c vs. placebo; albeit not to the same ... Citation: Mearns ES, Sobieraj DM, White CM, Saulsberry WJ, Kohn CG, Doleh Y, et al. ... Funding: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). ...... Phung OJ, Scholle JM, Talwar M, Coleman CI.

More Info

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC ...

search.rpxcorp.com

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC PHARM CO. , LTD. et al. 3:15-cv-05982; Filed: 08/04/2015; Case Updated Daily; Latest ...

1998-Present | The Center for Professional Responsibility

www.americanbar.org

Providence Community Corrections, Inc., et al, No.16-5058, United States Court of ... of Pennsylvania, December 4, 2015; Boehringer Ingelheim Pharmaceuticals, Inc., v. .... al. v. M. Plata and R.Coleman, et al., United States Supreme Court No.

External Validation of Generic and Cancer-Specific Risk ...

www.bloodjournal.org

3 days ago ... ... the general population at low vs. high risk of early (30 day) mortality. Font et al. applied similar risk stratification criteria in a population restricted to PE patients with cancer. ... Disclosures Coleman: Janssen Pharmaceuticals: Consultancy, ... Research Funding; Boehringer-Ingelheim Pharmaceuticals, inc.